Ipamorelin + PT-141 (Bremelanotide) Stack: Complete Protocol

What Each Peptide Does Independently

Ipamorelin and PT-141 work through separate biological pathways with no known shared receptor target. Understanding each mechanism individually is the foundation for any rational stacking decision.

Ipamorelin: Selective Growth Hormone Release

Ipamorelin is a pentapeptide that binds the ghrelin receptor (GHSR-1a) and triggers pulsatile growth hormone (GH) release from the anterior pituitary. Unlike older GHRPs such as GHRP-6, ipamorelin does not meaningfully raise cortisol or prolactin at standard doses, a property confirmed in rat and porcine models and frequently cited in clinical peptide discussions [1, 2].

A 2001 paper in the Journal of Endocrinology demonstrated that ipamorelin produced dose-dependent GH release in rats without significant ACTH or cortisol elevation, distinguishing it from GHRP-2 and GHRP-6 [1]. The downstream effects of elevated GH include increased IGF-1 production, improved nitrogen retention, and enhanced lipolysis. These outcomes depend heavily on pulsatile timing, flat, continuous GH elevation desensitizes receptors [2].

PT-141 (Bremelanotide): Central Melanocortin Activation

PT-141, marketed under the brand name Vyleesi, is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). It binds melanocortin receptors MC3R and MC4R in the central nervous system, particularly in the hypothalamus, to increase sexual desire through a neurogenic pathway that bypasses vascular mechanisms entirely [3].

The FDA approved PT-141 in June 2019 specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women, making it one of the very few centrally acting pharmacological agents for female sexual dysfunction. The key RECONNECT trials (N=1,247 combined across two trials) showed statistically significant improvements in satisfying sexual events and Female Sexual Function Index desire scores vs. Placebo at 1.75 mg [4].

Unlike PDE5 inhibitors, PT-141 does not act on peripheral vasculature as its primary mechanism. This is a clinically meaningful distinction because it means the drug may produce arousal even when vascular factors are limiting, and it raises no theoretical conflict with growth hormone signaling [3].

Why Practitioners Stack These Two Peptides

The rationale for combining ipamorelin and PT-141 rests on three arguments: non-overlapping receptors, additive lifestyle goals, and no documented pharmacokinetic interaction.

Receptor Non-Overlap

Ipamorelin occupies GHSR-1a. PT-141 occupies MC3R and MC4R. These are structurally unrelated G-protein-coupled receptors on different cell populations. No published pharmacology paper identifies cross-talk between the ghrelin receptor axis and the melanocortin-4 receptor axis that would predict antagonism or potentiation at standard therapeutic doses [1, 3].

This non-overlap means neither peptide competes for the other's binding site, and receptor downregulation from one agent does not theoretically impair the other's efficacy.

Lifestyle Goal Combination Without Pharmacological Interaction

Many patients pursuing body composition optimization also report concerns about sexual desire, particularly when undertaking caloric restriction or significant training volume. Caloric restriction itself suppresses gonadotropin-releasing hormone pulsatility and can reduce libido [5]. Ipamorelin's GH-stimulating effect may support lean-mass preservation during a cut; PT-141 addresses desire directly through central melanocortin signaling. The two goals are compatible because they arise from different physiological deficits.

The Evidence Gap, What We Do Not Know

No published randomized controlled trial has evaluated ipamorelin and PT-141 in combination. The evidence base for this stack comes from mechanism extrapolation, individual agent trials, and practitioner-reported outcomes. Any clinician or patient using this combination must accept that additive or unexpected interactions have not been systematically excluded in human subjects. The FDA label for Vyleesi lists no drug interactions with growth hormone secretagogues specifically [3], but that reflects an absence of study rather than a confirmed absence of interaction.

Complete Dosing Protocol

The following protocol synthesizes FDA-label guidance for PT-141, published ipamorelin pharmacology, and practitioner consensus. It is not a substitute for individualized medical supervision.

Ipamorelin Dosing Parameters

Standard practitioner dosing for ipamorelin falls between 200 and 300 mcg per injection, administered subcutaneously. Practitioners typically prescribe one to three injections daily, timed to capitalize on the natural GH pulse windows: early morning (fasting), pre-training, and at bedtime [1, 2].

Bedtime dosing is the most commonly recommended single-dose schedule because slow-wave sleep coincides with the largest endogenous GH pulse, and ipamorelin amplifies rather than replaces that pulse [2]. Eating within 90 minutes before injection blunts the GH response via somatostatin release, so injections should be given in a fasted state when possible [2].

Cycle length in practitioner-reported protocols ranges from 8 to 16 weeks, followed by a 4-to-8-week off period to preserve receptor sensitivity. No published RCT establishes an optimal cycle length specifically for ipamorelin.

PT-141 Dosing Parameters

The FDA-approved dose for PT-141 is 1.75 mg subcutaneous injection administered at least 45 minutes before anticipated sexual activity, no more than once per 24 hours and no more than once per 72 hours in clinical practice to limit nausea accumulation [3]. A lower starting dose of 1.25 mg is listed in the label as an option for patients who experience significant nausea at 1.75 mg [3].

Injection site is typically the abdomen or thigh; the drug reaches peak plasma concentration in approximately 1 hour after subcutaneous administration [3].

PT-141 is not intended for daily use. The RECONNECT trials used an on-demand dosing model, and the approval reflects that design [4].

Stacking Timeline: A Day-by-Day Example

The table below maps a sample week for a patient using ipamorelin on a daily bedtime schedule while incorporating PT-141 on an as-needed basis. Ipamorelin is taken nightly; PT-141 is taken only on days when sexual activity is anticipated, observing the 72-hour spacing guidance many clinicians prefer.

| Day | Ipamorelin (bedtime, fasted) | PT-141 (on-demand) | Notes | |-----|-----------------------------|--------------------|-------| | Mon | 200 to 300 mcg SQ |, | Standard ipamorelin night dose | | Tue | 200 to 300 mcg SQ | 1.25 to 1.75 mg SQ, ~60 min before activity | Both peptides active; no timing conflict | | Wed | 200 to 300 mcg SQ |, | Resume single-agent ipamorelin | | Thu | 200 to 300 mcg SQ |, | | | Fri | 200 to 300 mcg SQ | 1.25 to 1.75 mg SQ, ~60 min before activity | Second PT-141 dose of week (72 h gap met) | | Sat | 200 to 300 mcg SQ |, | | | Sun | 200 to 300 mcg SQ |, | |

On days when both peptides are used, there is no documented pharmacokinetic reason to separate the injections by hours. Practitioners typically advise using different injection sites (e.g., left abdomen for ipamorelin, right thigh for PT-141) to minimize local tissue accumulation and make it easier to attribute any local reaction to a specific compound.

Safety Profile: Each Agent Separately and Together

Ipamorelin Safety

Ipamorelin's selective receptor profile makes it one of the better-tolerated GHRPs in the class. In the original rat studies, ACTH, cortisol, and prolactin responses were minimal compared to GHRP-6 at equivalent GH-releasing doses [1]. Reported adverse effects in clinical use include mild injection-site erythema, transient water retention (due to GH-mediated aldosterone effects), and occasional headache.

Long-term safety in humans has not been established by any completed RCT. GH excess from any source carries theoretical risks including glucose intolerance and, over very long durations, oncogenic concerns, though these have not been demonstrated at physiological GH-amplifying doses in published literature [2]. The FDA has not approved ipamorelin for any indication.

PT-141 Safety

The FDA label for Vyleesi lists nausea as the most common adverse event, occurring in approximately 40% of patients in the RECONNECT trials, with 13% rating it severe [3, 4]. Flushing (20%), headache (11%), and transient blood pressure increases (mean systolic increase of approximately 6 mmHg lasting 12 hours) were also reported [3].

PT-141 is contraindicated in patients with known cardiovascular disease, specifically uncontrolled hypertension and high cardiovascular risk, because of the transient blood pressure effects documented in the trials [3]. Patients should not take PT-141 with any antihypertensive that relies on central melanocortin pathways, a rare but real consideration in patients on specific weight-management agents.

Combined Safety Considerations

No published study has evaluated the combined safety of ipamorelin and PT-141 in human subjects. The theoretical concern with combining any GH secretagogue with a centrally acting neuropeptide is downstream hypothalamic crosstalk. The hypothalamus expresses both GHSR-1a and MC4R, and animal models suggest these receptors interact in appetite and energy regulation, but the clinical significance at the doses used therapeutically is unknown [5, 6].

Blood pressure monitoring is warranted on days PT-141 is used, regardless of ipamorelin co-administration. Patients with baseline hypertension should approach PT-141 with particular caution given the documented transient BP elevation [3].

Who May Benefit From This Stack

The clinical profile that practitioners most commonly associate with this combination is an adult patient, male or female, who is:

• Using ipamorelin as part of a body composition or recovery protocol
• Experiencing reduced sexual desire that may relate to caloric restriction, elevated training stress, or age-related hormonal decline
• Medically cleared for both agents independently (normal blood pressure, no cardiovascular contraindications)

Women with diagnosed HSDD who also have legitimate clinical indications for GH support represent the clearest population where PT-141's FDA-approved use could coexist with an off-label ipamorelin prescription. PT-141 is not approved in men, though off-label use in males with low desire has been described in the literature; a 2004 Phase 2 trial in men with erectile dysfunction (N=32) showed PT-141 produced erections superior to placebo without the hemodynamic profile of PDE5 inhibitors [7].

Men considering PT-141 use should discuss the off-label nature explicitly with a prescribing physician. The RECONNECT data apply to premenopausal women only [4].

Monitoring and Lab Work

Routine monitoring for anyone on ipamorelin typically includes IGF-1 levels (drawn fasting in the morning) at baseline and at 8-week intervals. IGF-1 is the most practical surrogate for cumulative GH activity. A target range is generally the upper third of age-adjusted normal, approximately 200 to 350 ng/mL in most adults, though specific targets should be individualized [2].

IGF-1 Targets

Clinicians generally aim to keep IGF-1 within the age-adjusted reference range rather than pushing it to supraphysiologic levels. Values consistently above 400 ng/mL in the absence of acromegaly warrant dose reduction or a treatment break. The Endocrine Society's clinical practice guideline on adult GH deficiency provides reference ranges and monitoring frameworks that practitioners adapt for secretagogue-supported patients [2].

Cardiovascular Monitoring on PT-141 Days

Blood pressure should be checked before each PT-141 administration. The FDA label specifies that PT-141 should not be used by patients with blood pressure greater than 165/95 mmHg, and that a blood pressure reading should be taken within 2 hours of injection to catch the peak pressor effect [3]. Systolic readings above 165 mmHg on PT-141 days should prompt withholding the dose and consulting the prescribing clinician.

Fasting Glucose

GH elevates fasting glucose transiently by opposing insulin's action on skeletal muscle glucose uptake [2]. Patients with impaired fasting glucose or early insulin resistance should monitor fasting glucose at baseline and every 8 weeks. The American Diabetes Association notes that GH excess is an established secondary cause of glucose intolerance [8].

Regulatory and Compounding Considerations

PT-141 (bremelanotide / Vyleesi) is FDA-approved and available through licensed pharmacies with a valid prescription [3]. Ipamorelin is not FDA-approved and is typically obtained through compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. The FDA has listed certain peptides as "difficult to compound" or subject to increased scrutiny, and compounded ipamorelin's regulatory status has shifted as enforcement priorities evolve [9].

Patients and clinicians should verify current FDA guidance on compounded peptides before initiating ipamorelin therapy, as availability through licensed compounders depends on the compound not appearing on the FDA's 503B list of prohibited substances [9]. Vyleesi (PT-141) autoinjectors are commercially manufactured and do not carry compounding regulatory risk.

Practical Administration Notes

Subcutaneous injections for both peptides are typically given with a 28 to 31 gauge, 0.5-inch needle into the pinched skin of the lower abdomen, outer thigh, or upper arm. Rotating injection sites prevents lipohypertrophy, which can slow absorption unpredictably.

Ipamorelin, like most peptides, requires refrigeration after reconstitution (if purchased lyophilized) and is typically stable for 30 days at 2 to 8°C after mixing with bacteriostatic water [1]. PT-141 (Vyleesi) is supplied as a prefilled autoinjector and requires no reconstitution.

Both compounds are administered by subcutaneous injection, not intramuscular. Intramuscular injection of PT-141 was used in some earlier trials but the approved route is subcutaneous [3].